Citius Pharmaceuticals Executes Definitive Agreement To Merge Wholly Owned Subsidiary With TenX Keane Acquisition To Form Publicly Listed Citius Oncology, Inc.
Citius Pharmaceuticals Executes Definitive Agreement To Merge Wholly Owned Subsidiary With TenX Keane Acquisition To Form Publicly Listed Citius Oncology, Inc.
Citius Pharmicals签署最终协议，将全资子公司与收购TenX Keane合并，组建上市的Citius Oncology, Inc.
Upon closing, pursuant to the terms of the merger agreement, Citius Pharma would receive 67.5 million shares in Citius Oncology at $10 per share and retain majority ownership of approximately 90%. The transaction has been approved by the Board of Directors of both companies and is expected to close in the first half of 2024.
收盘后，根据合并协议的条款，Citius Pharma将以每股10美元的价格获得Citius Oncology的6,750万股股份，并保留约90％的多数股权。该交易已获得两家公司董事会的批准，预计将于2024年上半年完成。